The investigation centers on allegations that Medline failed to provide accurate disclosures concerning its operational compliance. Tensions surfaced on June 2, 2026, when the FDA issued a warning letter citing significant violations of Current Good Manufacturing Practice regulations. Regulators noted that the company failed to adequately investigate batch discrepancies, causing Medline shares to drop 7% that day.

Financial instability deepened during the company’s second-quarter earnings call on August 5. Management admitted that remediation efforts required to address the FDA’s findings resulted in substantial earnings losses. This disclosure prompted a further 13% slide in the company's valuation. Bleichmar Fonti & Auld LLP is currently evaluating potential legal recourse for investors who suffered losses during this period, operating on a contingency fee basis.